Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1648BQL

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	May 12	EXTEND option available in structure searching
NEWS 4	May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS 5	May 27	New UPM (Update Code Maximum) field for more efficient patent SDIs in CAplus
NEWS 6	May 27	CAplus super roles and document types searchable in REGISTRY
NEWS 7	Jun 28	Additional enzyme-catalyzed reactions added to CASREACT
NEWS 8	Jun 28	ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG, and WATER from CSA now available on STN(R)
NEWS 9	Jul 12	BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS 10	Jul 30	BEILSTEIN on STN workshop to be held August 24 in conjunction with the 228th ACS National Meeting
NEWS 11	AUG 02	IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS 12	AUG 02	CAplus and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS 13	AUG 02	STN User Update to be held August 22 in conjunction with the 228th ACS National Meeting
NEWS 14	AUG 02	The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS 15	AUG 04	Pricing for the Save Answers for SciFinder Wizard within STN Express with Discover! will change September 1, 2004

NEWS EXPRESS	JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:52:29 ON 24 AUG 2004

=> file caplus biosis

COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION
FULL ESTIMATED COST | 0.42 | 0.42

FILE 'CAPLUS' ENTERED AT 15:53:34 ON 24 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE 'BIOSIS' ENTERED AT 15:53:34 ON 24 AUG 2004

=> HIV
L1 176430 HIV

=> humanized (w) monoclonal (w) antibody
L2 1066 HUMANIZED (W) MONOCLONAL (W) ANTIBODY

=> L1 and L2
L3 20 L1 AND L2

=> gp120 and L3
L4 5 GP120 AND L3

=> D L4 IBIB ABS 1-5

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:49959 CAPLUS
DOCUMENT NUMBER: 135:151297
TITLE: Virolysis and in vitro neutralization of **HIV**-1 by **humanized monoclonal antibody** hNM-01
AUTHOR(S): Nakamura, Mariko; Terada, Masaki; Sasaki, Hiroyuki; Kamada, Minori; Ohno, Tsuneya
CORPORATE SOURCE: Department of Microbiology, Jikei University School of Medicine, Tokyo, 105-8461, Japan
SOURCE: Hybridoma (2000), 19(6), 427-434
CODEN: HYBRDY; ISSN: 0272-457X
PUBLISHER: Mary Ann Liebert, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Antibody humanization by transplanting the complementarity determining region (CDR) to a human framework aims to reduce the response of the human immune system against a foreign mol. during passive immunization. We transferred the CDR from the murine monoclonal antibody (MAb) NM-01 to a human IgG frame. The humanized NM-01 (hNM-01) recognizes the same epitope on Human Immunodeficiency Virus type 1 (**HIV**-1) envelope as its murine progenitor, but with greater efficiency, and shows enhanced neutralization of **HIV**-1. We have shown that this increase in reactivity may be attributed to residue 4 of the humanized κ chain, where the presence of a methionine residue rather than the murine leucine appears to promote a more advantageous conformation of the antigen-binding site, perhaps via packing interactions with the Vκ CDR1. The capacity of humanized NM-01 to neutralize direct clin. isolates was also examined with the expectation that hNM-01 will prove suitable for development as a therapeutic agent. This reshaped antibody reacted with several clin. isolates of **HIV**-1 tested. Moreover, we proved the ability of this antibody of its activation of complement by flow cytometry and electron microscopy anal. Although hNM-01 alone was capable of neutralizing **HIV**-1, the presence of complement enhanced neutralization. The enhancement of complement activation was also observed in hNM-01 than murine progenitor. This finding supports a potential role for antibody-dependent complement-mediated virolysis and more effective neutralization in **HIV**-1 therapy.

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:908511 CAPLUS
DOCUMENT NUMBER: 135:44922
TITLE: Targeting **HIV**-1 **gp120** to the high affinity FC receptor (FCγRI, CD64) on myeloid antigen presenting cells: implications for enhancing vaccine responses
AUTHOR(S): Howell, Alexandra L.; Thacker, Tara N.; Li, Fang; Fiering, Steve; Graziano, Robert F.; Goldstein, Joel; Fanger, Michael W.
CORPORATE SOURCE: V.A. Medical Center, VT, 05009, USA
SOURCE: Current Topics in Virology (1999), 1, 61-70
CODEN: CTVUAG
PUBLISHER: Research Trends
DOCUMENT TYPE: Journal
LANGUAGE: English
AB We prepared a fusion protein containing a **humanized monoclonal antibody** (mAb), mAb H22, with specificity for the human high affinity Fc receptor for IgG (FcγRI, CD64), fused to **HIV**-1 **gp120**. This fusion protein construct was produced by joining the cDNA for the full length H22 heavy chain gene in frame to the cDNA for **gp120**. This construct, which also expressed a selectable marker, was stably transfected into a murine myeloma cell line that expressed the previously transfected H22 kappa light chain. The resulting fusion protein, (H22 + **gp120**), was secreted from the myeloma cell line and was purified by affinity chromatog. Flow cytometric anal. revealed that H22 + **gp120** bound with high affinity via the Fab portion of H22 to CD64 expressed on monocytes and macrophages from both humans and human CD64-expressing transgenic mice. Western blot anal. revealed that the 390 kDa fusion protein reacted with both anti-human IgG and anti-**gp120** mAbs. Incubation of a monocyte cell line with this fusion protein at 37°C resulted in internalization of the complex as determined by flow cytometric anal. Immunization of human CD64 transgenic mice with the purified H22 + **gp120** fusion protein induced higher titers of anti-**gp120** serum antibodies compared to immunization of non-transgenic littermates. Targeting **gp120** to CD64-expressing antigen presenting cells (APC) in vivo may augment immune responses and enhance protective immunity.
REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:25990 CAPLUS
DOCUMENT NUMBER: 130:80353
TITLE: Monoclonal antibodies which neutralize **HIV**-1 infection
INVENTOR(S): Chang, Tse Wen; Fung, Michael S. C.; Sun, Bill N. C.; Sun, Cecily R. Y.; Chang, Nancy T.
PATENT ASSIGNEE(S): Tanox, Inc., USA
SOURCE: U.S., 16 pp., Cont.-in-part of U.S. Ser. No. 767,533.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5854400	A	19981229	US 1992-950571	19920922
US 5981278	A	19991109	US 1991-767533	19910926
PRIORITY APPLN. INFO.:			US 1987-57445 B2	19870529

	US 1987-137861	B1 19871224
	US 1991-767533	A2 19910926

AB Murine monoclonal antibodies and related products such as antibody fragments, immunotoxins, human and humanized antibodies are disclosed, all of which bind to the **gp120** protein on the envelope of **HIV**-1. These antibodies and related products neutralize **HIV**-1. They inhibit the infection of T cells, and also inhibit syncytium formation. Further, the antibodies are preferably group-specific and neutralize various strains and isolates of **HIV** -1. These antibodies have a variety of uses, including the treatment of AIDS and ARC, the prevention of **HIV**-1 infection, as well as a diagnostic application, in that they can be used for assaying of unknown fluid samples for **HIV**-1.

REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1994:433148 CAPLUS
DOCUMENT NUMBER: 121:33148
TITLE: Design and construction of **humanized monoclonal antibodies** by model building using peptides with sequences similar to complementarity determining regions
INVENTOR(S): Harris, Linda J.; Bajorath, Jurgen; Hsiao, Ku Chuan
PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA
SOURCE: Can. Pat. Appl., 58 pp.
CODEN: CPXXEB
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2096860	AA	19931127	CA 1993-2096860	19930525
EP 578515	A2	19940112	EP 1993-401328	19930524
EP 578515	A3	19950510		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE

PRIORITY APPLN. INFO.: US 1992-888233 19920526

AB A method for designing **humanized monoclonal antibodies** by comparative model building is described. The complementarity-determining regions of the antibody are sequenced and compared to the sequences in a database of human proteins; these sequences are then modeled and tested to produce a model of the humanized antibody. Genes for the humanized Ig subunits are then constructed and expressed. The method is demonstrated by preparing a humanized antibody to CD18. Sequences from a Vg germline protein were found to be very similar to the mouse monoclonal antibody 60.3 light chain variable region and sequences from a human monoclonal antibody to **gp120** of **HIV**-1 were similar to the heavy chain variable region. The sequences were modeled to give minimal rms values for backbone deviation and the energy function. The genes for the two subunits were prepared by standard methods and expressed in Ag8.653 cells. The humanized antibody inhibited CR3(CD11b/CD18)-mediated uptake of zymosan by neutrophils as effectively as the original murine antibody.

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1992:529323 CAPLUS
DOCUMENT NUMBER: 117:129323
TITLE: The brightening prospect for AIDS vaccines
AUTHOR(S): Girard, Marc
CORPORATE SOURCE: Inst. Pasteur, Paris, 75724, Fr.
SOURCE: Uirusu (1991), 41(2), 129
CODEN: UIRUAF; ISSN: 0042-6857

DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review with no refs. in the field of AIDS vaccines. First, protection of chimpanzees against exptl. infection with **HIV**-1 was achieved by immunization of the animals with either the virus envelope glycoprotein **gp120** alone or with a variety of antigens, among which the envelope glycoprotein gp160 and a synthetic peptide with the sequence of the **HIV**-1 principal neutralization determinant. The latter, the V3 loop of **gp120**, is a highly variable, type-specific determinant. Antibodies to the V3 loop neutralize virus infectivity at a late stage of virus penetration by blocking fusion between the viral envelope and the membrane of the target cell. Protection of chimpanzees against **HIV** infection was also using only gp160 as a vaccine. Vaccine protection can also be demonstrated against **HIV**-infected cells (cell associated virus). The presence of V3-specific neutralizing antibodies seems to correlate in all cases with protection against virus challenge, whether the virus is cell-free or cell-associated Finally, a **humanized monoclonal antibody** to the V3 loop was able to provide passive protection to chimpanzees, thus confirming that the basis for protection against **HIV** infection lies in neutralizing antibodies.

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	24.43	24.85

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.50	-3.50

FILE 'STNGUIDE' ENTERED AT 15:56:08 ON 24 AUG 2004

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Aug 20, 2004 (20040820/UP).

spacer gif

Search History will be lost after eight hours of inactivity.
To combine searches use # before search number, e.g., #2 AND #6.
Search numbers may not be continuous; all searches are represented.
Click on query # to add to strategy

Entrez PubMed

PubMed Services

Related Resources

Search	Most Recent Queries	Time	Result
#74	Search **Skinner M 1988 and HTLV-III**	16:57:36	3
#73	Search **monoclonal antiboddy and 9284**	16:55:47	8
#70	Search **CD4 binding site and V3** Field: **All Fields**	16:42:18	166
#69	Search **CD4 binding site and V3**	16:42:10	166
#68	Search **CD4 binding site and V1/2**	16:42:02	0
#65	Search **Posner M 1991 and HIV**	16:26:36	3
#64	Search **Posner M 1991**	16:26:28	34
#63	Search **Poster M 1991**	16:22:15	0
#61	Search **page K 1992**	16:17:11	6
#58	Search **matthews T 1988 and HIV**	14:19:55	14
#57	Search **matthews T 1988**	14:19:48	28
#56	Search **Ivanoff L 1988**	14:19:14	0
#54	Search **Helseth E 1990**	14:15:44	5
#52	Search **Grimaila R 1992**	14:12:45	1
#50	Search **Freed E 1991 and HIV**	13:56:45	2
#48	Search **2F5 and HIV and human monoclonal antibody** Field: **All Fields,** Limits: **Publication Date to 1993/12/30**	13:46:28	3
#46	Search **2F5 and HIV and human monoclonal antibody** Field: **All Fields,** Limits: **Publication Date to 1994/12/20**	13:45:45	6
#43	Search **2F5 and HIV and human monoclonal antibody**	13:45:28	66
#45	Search **2F5 and HIV and human monoclonal antibody** Field: **All Fields,** Limits: **Publication Date to 1992/12/09**	13:45:19	0
#42	Search **2F5 and HIV and monoclonal antibody**	13:44:39	74
#41	Search **2F5 and HIV**	13:44:28	90
#40	Search **2F5**	13:44:22	173
#38	Search **2F5 antibody** Limits: **Publication Date to 1992/09/30**	13:43:35	10
#37	Search **2F5 and monoclonal antibody** Limits: **Publication Date to 1992/09/30**	13:43:14	7
#36	Search **2F5 and HIV** Limits: **Publication Date to**	13:42:56	0

	1992/09/30		
#34	Search **Broliden 1990** Limits: **Publication Date to 1992/09/30**	13:38:56	5
#31	Search **HIV and passive immunization and monoclonal** Limits: **Publication Date to 1992/09/30**	12:44:27	8
#30	Search **HIV and passive immunization** Limits: **Publication Date to 1992/09/30**	12:44:04	157
#29	Search **HI and passive immunization** Limits: **Publication Date to 1992/09/30**	12:43:54	56
#28	Search **HI and passive immunization 1992** Limits: **Publication Date to 1992/09/30**	12:43:46	1
#27	Search **Katinger H 1992** Limits: **Publication Date to 1992/09/30**	12:42:29	9
#26	Search **Buchacher A 1992** Limits: **Publication Date to 1992/09/30**	12:41:52	0
#24	Search **human monoclonal antibody and gp120** Field: **All Fields,** Limits: **Publication Date to 1992/09/30**	12:39:11	242
#23	Search **humanized antibody and gp120**	12:38:39	14
#22	Search **humanized antibody and gp120** Limits: **Publication Date to 1992/09/30**	12:38:35	0
#21	Search **humanized antibody and HIV** Field: **All Fields,** Limits: **Publication Date to 1992/09/30**	12:38:27	0
#20	Search **humanized antibody and HIV** Limits: **Publication Date to 1991/12/31**	12:38:05	0
#19	Search **humanized monoclonal antibody and HIV** Limits: **Publication Date to 1991/12/31**	12:37:55	0
#16	Search **bloliden 1991 and humanized monoclonal antibody** Field: **All Fields,** Limits: **Publication Date to 1991/12/31**	12:35:01	17
#15	Search **bloliden 1991 and humanized monoclonal antibody** Limits: **Publication Date to 1991/12/12**	12:34:38	16
#14	Search **bloliden 1991 and HIV antibody** Field: **All Fields,** Limits: **Publication Date to 1991/12/12**	12:28:31	602
#13	Search **bloliden 1991 and HIV antibody**	12:28:16	761
#12	Search **bloliden 1991 and HIV**	12:27:58	8907
#10	Search **Berkower 1991 and HIV**	12:27:03	2
#8	Search **burton 1991 and HIV**	12:22:26	1
#7	Search **burton 1991**	12:22:15	219
#5	Search **Moriuchi 1993 and HSV**	07:49:56	2
#2	Search **Weinheimer S and HSV**	07:46:42	8
#1	Search **Weinheimer S**	07:46:25	22

spacer gif

Search History will be lost after eight hours of inactivity.
To combine searches use # before search number, e.g., #2 AND #6.
Search numbers may not be continuous; all searches are represented.
Click on query # to add to strategy

Search	Most Recent Queries	Time	Result
#6	Search **human monoclonal antibody and HIV gp120 and neutralize** Limits: **Publication Date to 1994/01/06**	10:59:19	33
#9	Search **GorMy C 1991** Limits: **Publication Date to 1994/01/06**	10:22:44	33694
#8	Search **Gorny C 1991** Limits: **Publication Date to 1994/01/06**	10:22:34	0
#5	Search **83D4 and 2G12** Limits: **Publication Date to 1994/01/06**	10:18:03	1
#3	Search **human monoclonal antibody and HIV gp120** Field: **All Fields,** Limits: **Publication Date to 1994/01/06**	10:17:22	348
#1	Search **panka and antibody**	09:32:18	21

Clear History

for examination purposes, the claimed binding specificity of claims

read on the HIV binding specificity and is not limited to the particular epitope specificity of the claimed antibodies



Search History will be lost after eight hours of inactivity.
To combine searches use # before search number, e.g., #2 AND #6.
Search numbers may not be continuous; all searches are represented.
Click on query # to add to strategy

Entrez PubMed

PubMed Services

Related Resources

Search	Most Recent Queries	Time	Result
#68	Search **human monoclonal antibody and HIV and Fab** Field: **All Fields,** Limits: **Publication Date to 1992/09/30**	17:47:57	17
#67	Search **Buchacher 1992**	17:41:05	0
#66	Search **kang 1991 and HIV**	17:24:28	8
#65	Search **kang 1991 and HIV** Limits: **Publication Date to 1994/01/06**	17:23:44	5
#63	Search **jackson 1988 and HIV** Limits: **Publication Date to 1994/01/06**	17:22:42	18
#62	Search **jackson 1988** Limits: **Publication Date to 1994/01/06**	17:22:34	991
#60	Search **Ho D 1991 and HIV** Limits: **Publication Date to 1994/01/06**	17:21:27	10
#59	Search **Ho 1991 and HIV** Limits: **Publication Date to 1994/01/06**	17:21:19	22
#58	Search **Ho 1991** Limits: **Publication Date to 1994/01/06**	17:21:11	545
#57	Search **Tilley S 1992** Limits: **Publication Date to 1994/01/06**	17:10:30	3
#55	Search **Takeda A 1992 and antibody** Limits: **Publication Date to 1994/01/06**	15:59:17	5
#54	Search **Takeda A 1992** Limits: **Publication Date to 1994/01/06**	15:59:05	27
#53	**Related Articles** for **PubMed** (Select **2458487**)	15:49:49	202
#51	Search **Kinney-Thomas 1988** Limits: **Publication Date to 1994/01/06**	15:48:19	1
#50	Search **Kinney T and antibody** Limits: **Publication Date to 1994/01/06**	15:47:33	11
#49	Search **Kiney T and antibody** Limits: **Publication Date to 1994/01/06**	15:47:25	0
#48	Search **Kiney-Thomas 1988** Limits: **Publication Date to 1994/01/06**	15:47:05	0
#47	Search **abbott 3 and monoclonal antibody** Limits: **Publication Date to 1994/01/06**	15:38:15	56

#46	Search **abbott 3** Limits: **Publication Date to 1994/01/06**	15:38:06	1472
#45	Search **Gerald R and abbott 3** Limits: **Publication Date to 1994/01/06**	15:37:57	0
#44	Search **Gerald R and human monoclonal antibody** Limits: **Publication Date to 1994/01/06**	15:37:39	0
#42	Search **Paul DA and 1987** Limits: **Publication Date to 1994/01/06**	15:35:52	12
#41	Search **Paul DA** Limits: **Publication Date to 1994/01/06**	15:35:42	30
#39	Search **McDougal JS 1987** Limits: **Publication Date to 1994/01/06**	15:34:10	4
#38	Search **Tilley S 1991 and HIV** Limits: **Publication Date to 1994/01/06**	14:21:57	1
#6	Search **human monoclonal antibody and HIV gp120 and neutralize** Limits: **Publication Date to 1994/01/06**	10:59:19	33
#9	Search **GorMy C 1991** Limits: **Publication Date to 1994/01/06**	10:22:44	33694
#8	Search **Gorny C 1991** Limits: **Publication Date to 1994/01/06**	10:22:34	0
#5	Search **83D4 and 2G12** Limits: **Publication Date to 1994/01/06**	10:18:03	1
#3	Search **human monoclonal antibody and HIV gp120** Field: **All Fields,** Limits: **Publication Date to 1994/01/06**	10:17:22	348
#1	Search **panka and antibody**	09:32:18	21

Clear History